Related references
Note: Only part of the references are listed.Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Pharmacogenomic Contribution to Drug Response
Roshawn G. Watson et al.
CANCER JOURNAL (2011)
Personalized Medicine: The Road Ahead
Rutika Mehta et al.
CLINICAL BREAST CANCER (2011)
The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies
Zhiwei Chen et al.
MUTAGENESIS (2011)
Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis
Theodoros N. Sergentanis et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls
Xiangyu Ma et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
J. Bray et al.
BRITISH JOURNAL OF CANCER (2010)
The Frameshift Polymorphism CYP3A43_74_delA Is Associated With Poor Differentiation of Breast Tumors
Christina Justenhoven et al.
CANCER (2010)
Personalized treatment of early-stage breast cancer: Present concepts and future directions
Nadia Harbeck et al.
CANCER TREATMENT REVIEWS (2010)
Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
Kazuma Kiyotani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen
Rikje Ruiter et al.
PHARMACOGENOMICS (2010)
Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study
Priya P. Gor et al.
BREAST CANCER RESEARCH (2010)
Polymorphisms of drug-metabolizing genes and risk of non-Hodgkin lymphoma
Hee Nam Kim et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results
Vasiliki Michalaki et al.
ANTI-CANCER DRUGS (2009)
Association Studies of CYP1A1 and GSTM1 Polymorphisms with Esophageal Cancer Risk: Evidence-based Meta-analyses
Wen-Lei Zhuo et al.
ARCHIVES OF MEDICAL RESEARCH (2009)
Genetic Associations of 115 Polymorphisms with Cancers of the Upper Aerodigestive Tract across 10 European Countries: The ARCAGE Project
Cristina Canova et al.
CANCER RESEARCH (2009)
Anthracycline- and/or Taxane-Resistant Breast Cancer: Results of a Literature Review to Determine the Clinical Challenges and Current Treatment Trends
Alvaro Moreno-Aspitia et al.
CLINICAL THERAPEUTICS (2009)
Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
Stephen Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
Magnus Ingelman-Sundberg et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer
S. Marsh et al.
PHARMACOGENOMICS JOURNAL (2007)
Polymorphisms of cytochrome P450 1A1, glutathione S-transferase class mu, and tumour protein p53 genes and the risk of developing gallbladder cancer in Japanese
Yasuo Tsuchiya et al.
CLINICAL BIOCHEMISTRY (2007)
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer
Christoph Thussbas et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Genetic polymorphisms in the cytochrome P450 1A1 and 2E1 genes, smoking, drinking and prostate cancer susceptibility:: A case-control study in a Han nationality population in Southern China
Jie Yang et al.
INTERNATIONAL JOURNAL OF UROLOGY (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer
Y Xu et al.
CLINICAL CANCER RESEARCH (2005)
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer
WP Petros et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future
M Ingelman-Sundberg
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm
D Aktas et al.
GYNECOLOGIC ONCOLOGY (2002)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
J O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population
M Murata et al.
CANCER LETTERS (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
